AVX-470: A novel oral Anti-TNF antibody with therapeutic potential in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2273-2281

  Bhol, Kailash C ^a   Tracey, Daniel E ^a   Lemos, Brenda R ^a   Lyng, Gregory D ^b   Erlich, Emma C ^a   Keane, David M ^a   Quesenberry, Michael S ^a   Holdorf, Amy D ^a   Schlehuber, Lisa D ^a   Clark, Shawn A ^c   Fox, Barbara S ^a  

^a Avaxia Biologics Inc   (United States)

^b Biomodels   (United States)

^c Xtal BioStructures Inc   (United States)

Author keywords

Gut targeted; Polyclonal; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

AVX 470; AVX 470M; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; PREDNISOLONE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLOSTRUM; CONTROLLED STUDY; DAIRY CATTLE; DRUG BINDING; DRUG ISOLATION; DRUG POTENCY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; INTESTINE ENDOSCOPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CATTLE; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; INFLAMMATION; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888258983     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182a11958     Document Type: Article

References (35)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42; quiz e30.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521.
4. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458-466.
5. Sands BE. Why do anti-tumor necrosis factor antibodies work in Crohns disease Rev Gastroenterol Disord. 2004;4(suppl 3):S10-S17.
6. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008; 117:244-279.
7. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
8. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010;10:308-315.
9. Sandborn WJ. State-of-the-art: Immunosuppression and biologic therapy. Dig Dis. 2010;28:536-542.
10. Roos N, Mahe S, Benamouzig R, et al. 15N-labeled immunoglobulins from bovine colostrum are partially resistant to digestion in human intestine. J Nutr. 1995;125:1238-1244.
11. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362-381.
12. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
13. Murthy S, Cooper HS, Yoshitake H, et al. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphateinduced mouse colitis. Aliment Pharmacol Ther. 1999;13:251-260.
14. Hamilton MJ, Sinnamon MJ, Lyng GD, et al. Essential role for mast cell tryptase in acute experimental colitis. Proc Natl Acad Sci U S A. 2011; 108:290-295.
15. Tsujimoto M, Yip YK, Vilcek J. Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci U S A. 1985;82:7626-7630.
16. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3:96ra76.
17. Bhol KC, Schechter PJ. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig Dis Sci. 2007;52:2732-2742.
18. Griffiths CE, Barker JN, Kunkel S, et al. Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNFalpha) in allergic contact dermatitis (rhus dermatitis). Br J Dermatol. 1991;124:519-526.
19. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 2001;29:e45.
20. Goldberg ME, Djavadi-Ohaniance L. Methods for measurement of antibody/antigen affinity based on ELISA and RIA. Curr Opin Immunol. 1993;5:278-281.
21. Sheehan KC, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol. 1989;142:3884-3893.
22. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308-316.
23. Meager A. Measurement of cytokines by bioassays: theory and application. Methods. 2006;38:237-252.
24. Atreya R, Zimmer M, Bartsch B, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology. 2011;141:2026-2038.
25. Paiotti AP, Miszputen SJ, Oshima CT, et al. Etanercept attenuates TNBSinduced experimental colitis: role of TNF-alpha expression. J Mol Histol. 2011;42:443-450.
26. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
27. Alessandroni L, Kohn A, Cosintino R, et al. Local injection of infliximab in severe fistulating perianal Crohns disease: An open uncontrolled study. Tech Coloproctol. 2011;15:407-412.
28. Worledge KL, Godiska R, Barrett TA, et al. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci. 2000;45:2298-2305.
29. Greenberg PD, Cello JP. Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:348-354.
30. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136-151.
31. Alexander JS, Chaitanya GV, Grisham MB, et al. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci. 2010; 1207(suppl 1):E75-E85.
32. Kuo TT, Baker K, Yoshida M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30:777-789.
33. Ober RJ, Radu CG, Ghetie V, et al. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol. 2001;13:1551-1559.
34. Charmot D. Non-systemic drugs: A critical review. Curr Pharm Des. 2012;18:1434-1445.
35. Vazquez-Roque MI, Bouras EP. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome. Adv Ther. 2013;30:203-211.